CRL monthly performance report
Check CRL's monthly returns, drawdown, and seasonality trends — updated every month.
CRL monthly report
—
Key takeaways
- Charles River Laboratories (CRL) closed September 2026 at $273.41, down 5.15% for the month and +80.35% over the trailing 12 months.
- Year-to-date, CRL is +37.06%, outperforming the S&P 500 which has returned +10.58% YTD.
- The stock is trading +34.87% versus its 200-day moving average ($202.73), a bullish technical signal.
- Over the past three years, CRL has underperformed the S&P 500 by −38.55%, with a relative strength index reading of 76.4.
- Win rate over the trailing 39 months stands at 43.6% — 17 positive months versus 22 negative months.
Charles River Laboratories ended September 2026 at $273.41, posting a monthly return of −5.15%. The S&P 500 returned −1.69% over the same window, leaving relative performance at −3.45%.
The current quarter stands at +20.56% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +34.87% versus the 200-day moving average ($202.73).
Year-to-date, CRL is +37.06% against SPY +10.58%, a gap of +26.48%. The stock is currently −9.86% below its 52-week high, with maximum 3-year drawdown at −63.52%.
| Period | CRL | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.19% | −0.44% | +0.64% |
| 1 Week | −1.77% | −1.10% | −0.68% |
| 1 Month | −5.15% | −1.69% | −3.45% |
| 3 Months | +45.81% | −0.10% | +45.91% |
| 6 Months | +61.87% | +13.21% | +48.66% |
| YTD | +37.06% | +10.58% | +26.48% |
| 12 Months | +80.35% | +14.25% | +66.10% |
| 3 Years | +31.52% | +70.07% | −38.55% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +25.50% |
| #2 | Aug 2026 | +23.97% |
| #3 | Dec 2023 | +19.95% |
| #4 | Jul 2024 | +18.16% |
| #5 | Feb 2024 | +17.53% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2025 | −21.19% |
| #2 | Aug 2024 | −18.99% |
| #3 | Apr 2024 | −15.48% |
| #4 | Feb 2026 | −15.20% |
| #5 | Oct 2023 | −14.09% |
| Quarter | Return |
|---|---|
| Q2 2025 | +0.80% |
| Q3 2025 | +3.12% |
| Q4 2025 | +27.50% |
| Q1 2026 | −13.53% |
| Q2 2026 | +31.47% |
| Q3 2026 (QTD) | +20.56% |
| Year | Return |
|---|---|
| 2023 | +8.49% |
| 2024 | −21.91% |
| 2025 | +8.06% |
| 2026 | +37.06% |
| Metric | Value |
|---|---|
| 52-Week High | $303.31 (2026-08-27) |
| 52-Week Low | $144.26 (2025-09-25) |
| Current Price | $273.41 |
| 200-Day Moving Average | $202.73 |
| Price vs 200DMA | +34.87% |
| 3-Year Maximum Drawdown | −63.52% (2025-04-11) |
| Current Drawdown from 52W High | −9.86% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 76.4 |
| 3-Year Excess Return vs S&P 500 | −38.55% |
| RS Peak | 110.6 (Mar 2024) |
| RS Trough | 39.4 (Apr 2025) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was CRL's return for this report period?
CRL returned −5.15% in the latest monthly window ending 2026-09-16.
Has CRL outperformed SPY year to date?
YTD CRL: +37.06% vs SPY: +10.58%.
What is CRL's 12-month return?
+80.35% over the trailing 12 months.
Is CRL above or below its 200-day moving average?
Price is +34.87% versus 200DMA ($202.73).
What is the maximum drawdown in the 3-year window?
−63.52% on 2025-04-11.